Skip to main content
Premium Trial:

Request an Annual Quote

Microarrays: Ongoing MARG Study to Tell Array Users What to Expect


Last month, the Association for Biomolecular Resource Facilities’ Microarray Research Group committee expected to launch its industry-wide survey of microarray variability, based on an earlier study confined to MARG member labs. Led by chair Andrew Brooks, a professor at the University of Rochester Medical Center, MARG hopes that the study will create a benchmark for investigators to compare their microarray results.

Array users can find instructions on the ABRF website to deposit their array data at an FTP site located at Rochester’s genome center. Data collected will record the type of chip, lot number, species, and tissue type. Brooks emphasizes that to maintain anonymity, nothing will be recorded about biology or the particular experiment a chip was involved in. The goal is to analyze the same types of information as the pilot study, according to Brooks: “3’ and 5’ ratios for integrity, hybridization studies, control genes as indicators for chip reproducibility, overall number of genes, and their presence or absence.” The study is also expected to reveal sources of variability on Affy chips, “which we know is probably going to give us different results from what they see,” Brooks says.

The data collection should end late this month, with results published in a peer-reviewed publication. “We want people to have a benchmark to be able to see what everyone else is doing,” he says. One idea: “access to a database that says, ‘This is what 900 mouse liver arrays look like.’ It’ll be really helpful … to smaller labs and core facilities” in particular, Brooks says.

Even before the FTP site launched, a major pharma and large academic lab had committed to submit more than 1,000 arrays to the study. “I think it’s going to be a good turnout,” Brooks says.

— Meredith Salisbury

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.